CG Oncology Inc CGON
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
CG Oncology to Present at Upcoming Investor Conferences in September
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
Trading Information
- Previous Close Price
- $72.64
- Day Range
- $72.49–75.19
- 52-Week Range
- $37.01–80.97
- Bid/Ask
- $70.70 / $75.74
- Shares Outstanding
- 89.32M
- Market Cap
- $6.49B
- Volume/Avg
- 890,170 / 944,593
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,006.37
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 142
- Website
- https://www.cgoncology.com
Valuation
Metric | CGON |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.55 |
Price/Sales | 1,006.37 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | CGON |
|---|---|
Quick Ratio | 21.22 |
Current Ratio | 21.70 |
Interest Coverage | — |
Quick Ratio
CGON
Profitability
Metric | CGON |
|---|---|
Return on Assets (Normalized) | −19.85% |
Return on Equity (Normalized) | −20.88% |
Return on Invested Capital (Normalized) | −23.69% |
Return on Assets
CGON
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|FZg!!Dl | LOCK|P>HGH | $139B | |||
| Moderna Inc MRNA | LOCK|L^>@ds | LOCK|#@j | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|tJ?@Cjx | LOCK|$$$Z | $95B | |||
| argenx SE ADR ARGX | LOCK|!B^?Ll% | LOCK|fH< | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|xF%wRz | LOCK|hSq | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|?Y<^pV!L | LOCK|KPb@ | $31B | |||
| Incyte Corp INCY | LOCK|$THb$?? | LOCK|^&S | $25B | |||
| BioNTech SE ADR BNTX | LOCK|!@f<D$ | LOCK|?%< | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|KT#^df | LOCK|$#^> | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|LhDxg^ | LOCK|z? | $16B |
United States